Vonoprazan + Placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
47
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Non-Erosive Gastro-Esophageal Reflux Disease
Conditions
Non-Erosive Gastro-Esophageal Reflux Disease, Heartburn
Trial Timeline
Mar 25, 2021 → Jan 17, 2022
NCT ID
NCT04799158About Vonoprazan + Placebo
Vonoprazan + Placebo is a phase 2 stage product being developed by Phathom Pharmaceuticals for Non-Erosive Gastro-Esophageal Reflux Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT04799158. Target conditions include Non-Erosive Gastro-Esophageal Reflux Disease, Heartburn.
Hype Score Breakdown
Clinical
17
Activity
12
Company
5
Novelty
5
Community
5
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06851559 | Phase 2 | Recruiting |
| NCT05195528 | Phase 3 | Completed |
| NCT04799158 | Phase 2 | Completed |
Competing Products
6 competing products in Non-Erosive Gastro-Esophageal Reflux Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| YH1885L(Revaprazan) + Esomeprazole 20mg + placebo | Yuhan | Phase 2 | 52 |
| E3810 + E3810 + Placebo | Eisai | Phase 3 | 77 |
| RABEPRAZOLE SODIUM + RABEPRAZOLE SODIUM | Eisai | Phase 3 | 77 |
| Omeprazole | AstraZeneca | Phase 3 | 77 |
| Omeprazole | AstraZeneca | Phase 3 | 77 |
| Vonoprazan + Placebo | Phathom Pharmaceuticals | Phase 3 | 72 |
Other Products from Phathom Pharmaceuticals
PYTEST® 14C-Urea Capsule Breath Test (at Home) + PYTEST® 14C-Urea Capsule Breath Test (Standard Retesting In-Person)Approved
80
PYTEST® 14C-Urea Breath Test + VOQUEZNA® Triple Pak®Approved
80
Vonoprazan + LansoprazolePhase 3
72
Vonoprazan + Amoxicillin + Clarithromycin + LansoprazolePhase 3
72
Vonoprazan + PlaceboPhase 3
72